![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1722719
½ÉÇ÷°ü ÁßÀç½Ã¼ú ±â±â ½ÃÀå º¸°í¼ : Á¦Ç°, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)Interventional Cardiology Devices Market Report by Product (Stents, Interventional Catheters, PTCA Guidewires, Balloon Inflation Device, PTCA Balloons), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Region 2025-2033 |
¼¼°è ½ÉÇ÷°ü ÁßÀç½Ã¼ú ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 245¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö 432¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 6.53%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, Àα¸ °í·ÉÈ, Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü, ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú·ÎÀÇ Àüȯ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
½ÉÇ÷°ü ÁßÀç½Ã¼ú ±â±â´Â Ç÷°ü¼ºÇü¼ú, ½ºÅÙÆ® »ðÀÔ¼ú µî ½ÉÇ÷°ü ½Ã¼ú¿¡ »ç¿ëµÇ´Â ÀÇ·á±â±â ¹× °¡ÀÌµå µµ±¸¸¦ ¸»ÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ±â±â¿¡´Â Ç÷°ü¼ºÇü¼ú¿ë dz¼±, ½ºÅÙÆ®, ½Â¸ðÆÇ¸·, Æóµ¿¸ÆÆÇ¸·, »ï÷ÆÇ¸·, Ä«Å×ÅÍ, ÇöóÅ© ¼öÁ¤ ÀåÄ¡, Ç÷¿ªÇÐ º¯°æ ÀåÄ¡ µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² °¡À̵å¿ÍÀ̾î, Ç÷°ü Æó¼â ¹× ÁöÇ÷ ±â±¸, ÀÎÆ®·Îµà¼ ½Ã½º(Introducer Sheath)µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±â ¹× ÀåÄ¡´Â °ü»óµ¿¸Æ¿ìȸ¼ú(CABG), °æ½É±Ù ·¹ÀÌÀú Ç÷ÇàÀç°Ç¼ú(TMR), ºÎÁ¤¸Æ Ä¡·á, µ¿¸Æ·ù Ä¡·á, °³½É¼ú, ¿ÀÇÁÆßÇÁ ½ÉÀå¼ö¼ú, ÃÖ¼Òħ½À(MI) ½ÉÀå¼ö¼ú µîÀÇ ÀÇ·á ½Ã¼ú¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¿¸ÆÀýÁ¦¼ú, »öÀüÁõ ¿¹¹æ, °æÇÇÀû ÆÇ¸· ¼ºÇü¼ú µî ´Ù¸¥ ½Ã¼ú¿¡µµ »ç¿ëµË´Ï´Ù.
´ç´¢º´, °íÇ÷¾Ð, °ü»óµ¿¸ÆÁúȯ(CAD)°ú °°Àº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Áúº´¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÁßÀçÀû ½ÉÀåÇÐ ¹× »öÀü ¹æÁö ÀåÄ¡´Â Ç÷Àü ÆÄÆíÀ» Æ÷ÂøÇÏ¿© Ç÷·ù¸¦ º¸ÀåÇÏ°í ¸·ÈûÀ» ¹æÁöÇϱâ À§ÇØ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çõ½ÅÀûÀÎ »ýü Èí¼ö¼º ½ºÅÙÆ®, ¾à¹° ¿ëÃ⼺ ½ºÅÙÆ®, ½É¹ÚÁ¶À²±â, ¾à¹° ÄÚÆÃ ¸Þ½¬ Æ©ºêÀÇ °³¹ßµµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ½ÉÇ÷°ü ÁúȯÀÇ Á¶±â Áø´Ü ¹× Àû½Ã Ä¡·á¸¦ À§ÇØ Á¤¸Æ ³» ÃÊÀ½ÆÄ(IVUS), ºÐȹÇ÷·ù¿¹ºñ·®(FFR), ±¤°£¼·´ÜÃþÃÔ¿µ(OCT)°ú °°Àº ÷´Ü ¿µ»ó ¼Ö·ç¼ÇÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ½ÅÈï °æÁ¦±¹À» Áß½ÉÀ¸·Î ÀÇ·á ÀÎÇÁ¶ó°¡ È®ÃæµÇ°í ´ëÁßÀÇ ÀÇ·áºñ ÁöÃâ ´É·ÂÀÌ Çâ»óµÇ¸é¼ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
The global interventional cardiology devices market size reached USD 24.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 43.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.53% during 2025-2033. The rising prevalence of cardiovascular diseases, aging population, ongoing technological advancements, and increasing shift towards minimally invasive procedures are primarily driving the market's growth.
Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting. Some of the commonly used devices include angioplasty balloons, stents, mitral, pulmonary and tricuspid valves, catheters, plaque modification and hemodynamic flow alteration devices. Along with this, guidewires, vascular closure and hemostasis devices and introducer sheaths are also utilized. These tools and devices are widely used for medical procedures, such as coronary artery bypass grafting (CABG), trans-myocardial laser revascularization (TMR), arrhythmia treatment, aneurysm repair, open-heart, off-pump heart and minimally invasive (MI) heart surgeries. They are also used for other procedures, such as atherectomy, embolic protection and percutaneous valve repair.
The increasing prevalence of diabetes, hypertension and cardiovascular disorders, such as coronary artery disease (CAD, is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Interventional cardiology and embolic protection devices are widely used to capture embolic debris to ensure continuous blood flow and preventing blockages. Additionally, the development of innovative bioabsorbable and drug-eluting stents, pacemakers and drug-coated mesh tubes is acting as another growth-inducing factor. In line with this, the increasing utilization of advanced imaging solutions, such as intravenous ultrasound (IVUS), fractional flow reserve (FFR) and optical coherence tomography (OCT) for early diagnosis and timely treatment of cardiovascular ailments, is also contributing to the growth of the market. Other factors, including rising healthcare expenditure capacities of the masses, along with extensive improvements in the medical infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Alvimedica, B. Braun Melsungen AG, Biosensors International Group Ltd. (Bluesail Medical Co. Ltd.), BIOTRONIK Inc., Boston Scientific Corporation, Cook Group Incorporated, ENDOCOR GmbH, Koninklijke Philips N.V., Medinol Ltd., Medtronic plc and Terumo Corporation.